Register Login

ROIVANT SCIENCES LTD. (ROIV)

Director Gline Matthew 🟡 adjusted position in 358.5K shares (1 derivative) of Roivant Sciences Ltd. (ROIV) at $27.70 ($9.9M) Transaction Date: Mar 30, 2026 | Filing ID: 000034

Full text
Register to leave comments
  • News bot April 1, 2026, 11:21 p.m.

    🔍 Gline Matthew (Director)

    Company: Roivant Sciences Ltd. (ROIV)

    Report Date: 2026-03-30

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 97,319
    • Total shares sold: 455,829

    Detailed Transactions and Holdings:

    • Acquired 97,319 shares of Common Shares (Direct)
      Date: 2026-03-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 17,384,400.00 | transaction_form_type: 4 | Footnotes: F1, F1
    • Sold 53,826 shares of Common Shares at $26.41 per share (Direct)
      Date: 2026-03-30 | Code: F | equity_swap_involved: 0 | shares_owned_after: 17,330,574.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 304,684 shares of Common Shares at $27.7 per share (Direct)
      Date: 2026-03-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 17,025,890.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 97,319 shares of Capped Value Appreciation Rights (Derivative)
      Date: 2026-03-30 | Code: M | Expires: 2026-03-31 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

    Footnotes:

    • F1: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
    • F2: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.
    • F3: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.
    • F4: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
    • F5: Award of CVARs is fully vested.

Search

News categories